BetterLife Pharma Inc. (BETRF)
USD 0.06
(-0.62%)
USD 0.06
(-0.62%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.47 Million | -1.5 Million | -11.2 Million | -7.16 Million | -7.88 Million | -4.97 Million |
| Net Income | -2.88 Million | -9.37 Million | -12.15 Million | -36.35 Million | -19.58 Million | -9.14 Million |
| Depreciation & Amortization | - | 18.43 Thousand | 18.43 Thousand | 342.81 Thousand | 1.4 Million | 900.65 Thousand |
| Deferred income taxes | - | - | - | 11.34 Million | 7.92 Million | 1.32 Million |
| Stock-based compensation | 500.26 Thousand | 951.06 Thousand | 1.23 Million | 826.63 Thousand | 1.59 Million | 31.56 Thousand |
| Change in working capital | 321.6 Thousand | 3.43 Million | -1.31 Million | -1.54 Million | 302.11 Thousand | 727.79 Thousand |
| Other non-cash items | 117.36 Thousand | 3.46 Million | 1.02 Million | 18.21 Million | 479.12 Thousand | 1.18 Million |
| Investing Cash Flow | - | - | - | -71.55 Thousand | -1.14 Million | -850.51 Thousand |
| Investments in PPE | - | - | - | -96.61 Thousand | -542.74 Thousand | -853.28 Thousand |
| Acquisitions | - | - | - | 25.06 Thousand | -432.92 Thousand | 2779.00 |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | -86.46 | -165.42 Thousand | -847.16 |
| Financing Cash Flow | 2.5 Million | 1.33 Million | 11.23 Million | 4.08 Million | 12.22 Million | 5.82 Million |
| Debt repayment | -300 Thousand | - | -250 Thousand | -499.92 Thousand | -3.83 Million | -770.52 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 2.2 Million | 833.31 Thousand | 11.44 Million | 1.28 Million | 16.31 Million | 1.53 Million |
| Other Financing Activities | 2.5 Million | 502.57 Thousand | 42.81 Thousand | 3.3 Million | -250 Thousand | 5.06 Million |
| Accounts receivables | -22.35 Thousand | 310 Thousand | 181.02 Thousand | -349.89 Thousand | -92.87 Thousand | -39.36 Thousand |
| Accounts payables | -701.56 Thousand | 2.21 Million | -1.15 Million | -993.93 Thousand | 1.05 Million | 470.78 Thousand |
| Inventory | - | -310 Thousand | -181.02 Thousand | 349.89 Thousand | 92.87 Thousand | - |
| Other working capital | 343.95 Thousand | 1.22 Million | -158.8 Thousand | -550.26 Thousand | -748.21 Thousand | 257 Thousand |
| Cash at beginning of period | 8307.00 | 173.51 Thousand | 154.72 Thousand | 3.28 Million | 74.8 Thousand | 79.3 Thousand |
| Cash at end of period | 37.38 Thousand | 8307.00 | 173.51 Thousand | 154.72 Thousand | 3.28 Million | 74.8 Thousand |
| Capital Expenditure | - | - | - | -96.61 Thousand | -542.74 Thousand | -853.28 Thousand |
| Effect of forex changes on cash | -56.00 | 2417.00 | -11.91 Thousand | 19.8 Thousand | 2218.00 | -3517.00 |
| Net cash flow / Change in cash | 29.07 Thousand | -165.2 Thousand | 18.79 Thousand | -3.12 Million | 3.2 Million | -4504.00 |
| Free Cash Flow | -2.47 Million | -1.5 Million | -11.2 Million | -7.26 Million | -8.42 Million | -5.83 Million |
| Breakdown | 2024 Q4 | 2024 FY | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.3 Million | -2.88 Million | -213.73 Thousand | -1.02 Million | -963.66 Thousand | -9.37 Million |
| Depreciation & Amortization | - | - | - | - | - | 18.43 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 61.46 Thousand | 500.26 Thousand | 112.32 Thousand | 232.2 Thousand | 94.26 Thousand | 951.06 Thousand |
| Change in working capital | 482.55 Thousand | 321.6 Thousand | 197.43 Thousand | 322.02 Thousand | -680.4 Thousand | 3.43 Million |
| Other non-cash items | 591.55 Thousand | 117.36 Thousand | -491.9 Thousand | 6925.00 | 194.86 Thousand | 3.46 Million |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 200 Thousand | 2.5 Million | 427.4 Thousand | 280 Thousand | 1.59 Million | 1.33 Million |
| Debt repayment | -300 Thousand | -300 Thousand | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -100 Thousand | - | - | - | - | - |
| Common Stock Issuance | 100 Thousand | 2.2 Million | 287.4 Thousand | 220 Thousand | 1.59 Million | 833.31 Thousand |
| Other Financing Activities | -200 Thousand | 2.5 Million | 140 Thousand | 60 Thousand | 1594.14 | 502.57 Thousand |
| Accounts receivables | -26.7 Thousand | -22.35 Thousand | -901.00 | 23.92 Thousand | -18.66 Thousand | 310 Thousand |
| Accounts payables | -82.8 Thousand | -701.56 Thousand | 63.35 Thousand | 62.74 Thousand | -744.86 Thousand | 2.21 Million |
| Inventory | - | - | 901.00 | -23.92 Thousand | 18.66 Thousand | -310 Thousand |
| Other working capital | 509.25 Thousand | 343.95 Thousand | 134.08 Thousand | 259.28 Thousand | 64.45 Thousand | 1.22 Million |
| Cash at beginning of period | 92.61 Thousand | 8307.00 | 60.99 Thousand | 247.47 Thousand | 8307.00 | 173.51 Thousand |
| Cash at end of period | 37.38 Thousand | 37.38 Thousand | 92.61 Thousand | 60.99 Thousand | 247.47 Thousand | 8307.00 |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | -103.00 | -56.00 | 98.00 | -14.00 | -37.00 | 2417.00 |
| Net cash flow / Change in cash | -55.23 Thousand | 29.07 Thousand | 31.62 Thousand | -186.48 Thousand | 239.16 Thousand | -165.2 Thousand |
| Free Cash Flow | -255.13 Thousand | -2.47 Million | -395.87 Thousand | -466.46 Thousand | -1.35 Million | -1.5 Million |
AUROPHARMA
GSTC
NCL
TW
IGLD-M
3648